

Moshe C Ornstein

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7268868/moshe-c-ornstein-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

797
citations

16
h-index

26
g-index

67
ext. papers

1,090
ext. citations

4.1
avg, IF

4.37
L-index

#	Paper	IF	Citations
64	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma 2018 , 6, 9		105
63	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1386-1394 ⁵⁰	21.7	50
62	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 1019-1040	2.9	43
61	State of the evidence: mechanical ventilation with PEEP in patients with cardiogenic shock. <i>Heart</i> , 2013 , 99, 1812-7	5.1	38
60	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab 2018 , 6, 107		36
59	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3088-3094	2.2	34
58	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 405-412	2.8	30
57	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019 , 25, 210-221	12.9	30
56	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1588-1593	2.2	29
55	A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1764-1769	2.2	26
54	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 160-163	8.7	25
53	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1237-e1242	2.2	24
52	Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 168-73	7.1	21
51	Combination strategies in myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2012 , 95, 26-33	2.3	20
50	More is better: combination therapies for myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 22-31	4.2	17
49	Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date. <i>Cancer Management and Research</i> , 2020 , 12, 4871-4881	3.6	16
48	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e879-e892	3.3	16

47	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e275-e280	3.3	16
46	The Immunotherapy Landscape in Renal Cell Carcinoma. <i>BioDrugs</i> , 2020 , 34, 733-748	7.9	16
45	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy 2019 , 7, 127		13
44	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 413-419.e1	3.3	13
43	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2536-42	1.9	12
42	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e437-e442	3.3	12
41	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 599-609	5	12
40	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018 , 13, 353-361	5	11
39	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 577-84	3.5	11
38	Emerging immunotherapy in advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 687-693	2.8	10
37	Imaging the immune response to monitor tumor immunotherapy. <i>Expert Review of Vaccines</i> , 2009 , 8, 1427-37	5.2	10
36	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 211-220	5	9
35	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e751-e760	3.3	9
34	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 262-268	2.8	9
33	Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 177-182	3.3	8
32	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. <i>Kidney Cancer</i> , 2017 , 1, 133-141	0.6	8
31	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. <i>JCO Oncology Practice</i> , 2021 , OP2100419	2.3	8
30	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018 , 78, 1035-1041	4.2	7

29	The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer Treatment and Research Communications</i> , 2020 , 23, 100169	2	5
28	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 500-508 ³	3.3	4
27	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 470.e19-470.e29	2.8	4
26	Pharmacokinetically Guided Dosing of Oral Drugs: True Precision Oncology?. <i>Clinical Cancer Research</i> , 2016 , 22, 5626-5628	12.9	4
25	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018 , 97, e12344	1.8	4
24	Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach. <i>JCO Oncology Practice</i> , 2020 , 16, 15s-19s	2.3	3
23	The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. <i>Journal of Kidney Cancer and VHL</i> , 2017 , 4, 10-18	1.4	3
22	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020 , 15, 477-483	5.83	2
21	Radical shifts in the first-line management of metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 71-72	19.4	2
20	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102938	2.2	2
19	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e47	1.2	1
18	Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 6246209	0.9	1
17	Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. <i>Targeted Oncology</i> , 2021 , 16, 813-821	5	1
16	Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 441-447	2.2	1
15	Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature. <i>Current Oncology</i> , 2021 , 28, 1921-1926	2.8	1
14	A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. <i>Targeted Oncology</i> , 2021 , 16, 633-642	5	1
13	Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab 2021 , 9,		1
12	Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis 2021 , 9,		1

11	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.. <i>European Urology</i> , 2021 ,	10.2	1
10	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e12-e16	3.3	0
9	Dying revisited: understanding the process, six years later. <i>Journal of Palliative Medicine</i> , 2013 , 16, 1479-80		
8	667. <i>Critical Care Medicine</i> , 2013 , 41, A163-A164	1.4	
7	674. <i>Critical Care Medicine</i> , 2013 , 41, A165	1.4	
6	Advances in Immune Monitoring Strategies for Cancer Vaccines and Immunotherapy 2007 , 269-289		
5	Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.. <i>Current Oncology</i> , 2021 , 28, 5019-5024	2.8	
4	Studying the association between breast cancer and renal cell carcinoma. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	
3	Moving the Needle Toward Improved Survival in Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2021 , OP2100614	2.3	
2	Impact of a Cancer Associated Thrombosis Clinic on Reducing Hospitalization for Venous Thromboembolism: The Cleveland Clinic Experience. <i>Blood</i> , 2015 , 126, 5588-5588	2.2	
1	Screening for functional kinases in metastatic prostate cancer: a glimmer of hope for kinase inhibition. <i>Translational Andrology and Urology</i> , 2016 , 5, 616-9	2.3	